Fig. 1: Lack of correlation between changes in plasma lyso-Gb3 and changes in LVMi, eGFR, and pain at selected timepoints of migalastat treatment. | Genetics in Medicine

Fig. 1: Lack of correlation between changes in plasma lyso-Gb3 and changes in LVMi, eGFR, and pain at selected timepoints of migalastat treatment.

From: Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease

Fig. 1

(a) Relationship between changes in lyso-Gb3 versus changes in LVMi. (b) Relationship between changes in lyso-Gb3 vs. changes in eGFR. (c) Relationship between changes in lyso-Gb3 versus changes in worst pain in 24 hours. eGFR estimated glomerular filtration rate, ERT enzyme replacement therapy, LVMi left ventricular mass index, lyso-Gb3 globotriaosylsphingosine, OLE open-label extension.

Back to article page